Brief: CytRx announces FDA's removal of partial clinical hold for Aldoxorubicin clinical trials

LadRx

20/01/2015 11:00

Jan 20 (Reuters) - CytRx Corp  CYTR.O : 
 * Announces FDA's removal of partial clinical hold for Aldoxorubicin clinical 
   trials permitting immediate enrollment of new patients 
 * Expects to complete enrollment in its ongoing pivotal global phase 3 trial in 
   second-line soft tissue sarcoma by the end of 2015 
 * Says market launch of aldoxorubicin for second line soft tissue sarcoma is 
   projected to commence in 2017 
 * Says company does not expect estimated timelines to materially change 
 * Enrollment and dosing of new patients now permitted after study sites' 
   institutional review boards approve revised trial protocols 
 * Source text for Eikon  ID:nPn2l5ZkX  
 * Further company coverage  CYTR.O   
 
 ((Bengaluru Newsroom; +1 646 223 8780))